"Global Cancer Diagnostics Market Overview:
Global Cancer Diagnostics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Cancer Diagnostics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Cancer Diagnostics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Cancer Diagnostics Market:
The Cancer Diagnostics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Cancer Diagnostics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Cancer Diagnostics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Cancer Diagnostics market has been segmented into:
Tumor Biomarkers Tests (PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
By Application, Cancer Diagnostics market has been segmented into:
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer Diagnostics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Cancer Diagnostics market.
Top Key Players Covered in Cancer Diagnostics market are:
Myriad Geneticsinc.
F. Hoffmann-La Roche AG
Invitae Corporation
NeoGenomics Laboratoriesinc.
BPS Bioscienceinc. Antibodies Inc.
Networks LLC
Beckman Coulterinc.
Euro Diagnostica AB
F. Hoffmann-La Roche Ltd.
Qiagen NV
Siemens Healthcare GmbH
Bio Rad Laboratories Inc.
Exagen Inc. Genway Biotechinc.
Microdrop LLC (imaware)
Svar Life Science AB
Abbott Laboratories
Thermo Fisher Scientific Inc.
Bio Rad Laboratories Inc.
GE Healthcare
Illuminainc.
Koninklijke Philips N.V.
Toshiba Medical Systems Corporation
Agilent Technologiesinc.
Aurora Imaging Technologiesinc.
Quest Diagnostics.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Cancer Diagnostics Market by Type
4.1 Cancer Diagnostics Market Snapshot and Growth Engine
4.2 Cancer Diagnostics Market Overview
4.3 Tumor Biomarkers Tests (PSA Tests
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Tumor Biomarkers Tests (PSA Tests: Geographic Segmentation Analysis
4.4 CTC Tests
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 CTC Tests: Geographic Segmentation Analysis
4.5 AFP Tests
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 AFP Tests: Geographic Segmentation Analysis
4.6 CA-19 Tests
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 CA-19 Tests: Geographic Segmentation Analysis
4.7 HER2 Tests
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 HER2 Tests: Geographic Segmentation Analysis
4.8 BRCA Tests
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 BRCA Tests: Geographic Segmentation Analysis
4.9 ALK Tests
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 ALK Tests: Geographic Segmentation Analysis
4.10 CEA Tests
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 CEA Tests: Geographic Segmentation Analysis
4.11 EGFR Mutation Tests
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Key Market Trends, Growth Factors and Opportunities
4.11.4 EGFR Mutation Tests: Geographic Segmentation Analysis
4.12 KRAS Mutation Tests
4.12.1 Introduction and Market Overview
4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.12.3 Key Market Trends, Growth Factors and Opportunities
4.12.4 KRAS Mutation Tests: Geographic Segmentation Analysis
4.13 Others
4.13.1 Introduction and Market Overview
4.13.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.13.3 Key Market Trends, Growth Factors and Opportunities
4.13.4 Others: Geographic Segmentation Analysis
Chapter 5: Cancer Diagnostics Market by Application
5.1 Cancer Diagnostics Market Snapshot and Growth Engine
5.2 Cancer Diagnostics Market Overview
5.3 Ultrasound
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Ultrasound: Geographic Segmentation Analysis
5.4 Mammography
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Mammography: Geographic Segmentation Analysis
5.5 MRI Scan
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 MRI Scan: Geographic Segmentation Analysis
5.6 PET Scan
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 PET Scan: Geographic Segmentation Analysis
5.7 CT Scan
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 CT Scan: Geographic Segmentation Analysis
5.8 SPECT & Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 SPECT & Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Cancer Diagnostics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 MYRIAD GENETICSINC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 F. HOFFMANN-LA ROCHE AG
6.4 INVITAE CORPORATION
6.5 NEOGENOMICS LABORATORIESINC.
6.6 AND BPS BIOSCIENCEINC. ANTIBODIES INC.
6.7 NETWORKS LLC
6.8 BECKMAN COULTERINC.
6.9 EURO DIAGNOSTICA AB
6.10 F. HOFFMANN-LA ROCHE LTD.
6.11 QIAGEN NV
6.12 SIEMENS HEALTHCARE GMBH
6.13 BIO RAD LABORATORIES INC.
6.14 EXAGEN INC. GENWAY BIOTECHINC.
6.15 MICRODROP LLC (IMAWARE)
6.16 SVAR LIFE SCIENCE AB
6.17 ABBOTT LABORATORIES
6.18 THERMO FISHER SCIENTIFIC INC.
6.19 BIO RAD LABORATORIES INC.
6.20 GE HEALTHCARE
6.21 ILLUMINAINC.
6.22 KONINKLIJKE PHILIPS N.V.
6.23 TOSHIBA MEDICAL SYSTEMS CORPORATION
6.24 AGILENT TECHNOLOGIESINC.
6.25 AURORA IMAGING TECHNOLOGIESINC.
6.26 AND QUEST DIAGNOSTICS.
Chapter 7: Global Cancer Diagnostics Market By Region
7.1 Overview
7.2. North America Cancer Diagnostics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Tumor Biomarkers Tests (PSA Tests
7.2.4.2 CTC Tests
7.2.4.3 AFP Tests
7.2.4.4 CA-19 Tests
7.2.4.5 HER2 Tests
7.2.4.6 BRCA Tests
7.2.4.7 ALK Tests
7.2.4.8 CEA Tests
7.2.4.9 EGFR Mutation Tests
7.2.4.10 KRAS Mutation Tests
7.2.4.11 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Ultrasound
7.2.5.2 Mammography
7.2.5.3 MRI Scan
7.2.5.4 PET Scan
7.2.5.5 CT Scan
7.2.5.6 SPECT & Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Cancer Diagnostics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Tumor Biomarkers Tests (PSA Tests
7.3.4.2 CTC Tests
7.3.4.3 AFP Tests
7.3.4.4 CA-19 Tests
7.3.4.5 HER2 Tests
7.3.4.6 BRCA Tests
7.3.4.7 ALK Tests
7.3.4.8 CEA Tests
7.3.4.9 EGFR Mutation Tests
7.3.4.10 KRAS Mutation Tests
7.3.4.11 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Ultrasound
7.3.5.2 Mammography
7.3.5.3 MRI Scan
7.3.5.4 PET Scan
7.3.5.5 CT Scan
7.3.5.6 SPECT & Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Cancer Diagnostics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Tumor Biomarkers Tests (PSA Tests
7.4.4.2 CTC Tests
7.4.4.3 AFP Tests
7.4.4.4 CA-19 Tests
7.4.4.5 HER2 Tests
7.4.4.6 BRCA Tests
7.4.4.7 ALK Tests
7.4.4.8 CEA Tests
7.4.4.9 EGFR Mutation Tests
7.4.4.10 KRAS Mutation Tests
7.4.4.11 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Ultrasound
7.4.5.2 Mammography
7.4.5.3 MRI Scan
7.4.5.4 PET Scan
7.4.5.5 CT Scan
7.4.5.6 SPECT & Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Cancer Diagnostics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Tumor Biomarkers Tests (PSA Tests
7.5.4.2 CTC Tests
7.5.4.3 AFP Tests
7.5.4.4 CA-19 Tests
7.5.4.5 HER2 Tests
7.5.4.6 BRCA Tests
7.5.4.7 ALK Tests
7.5.4.8 CEA Tests
7.5.4.9 EGFR Mutation Tests
7.5.4.10 KRAS Mutation Tests
7.5.4.11 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Ultrasound
7.5.5.2 Mammography
7.5.5.3 MRI Scan
7.5.5.4 PET Scan
7.5.5.5 CT Scan
7.5.5.6 SPECT & Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Cancer Diagnostics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Tumor Biomarkers Tests (PSA Tests
7.6.4.2 CTC Tests
7.6.4.3 AFP Tests
7.6.4.4 CA-19 Tests
7.6.4.5 HER2 Tests
7.6.4.6 BRCA Tests
7.6.4.7 ALK Tests
7.6.4.8 CEA Tests
7.6.4.9 EGFR Mutation Tests
7.6.4.10 KRAS Mutation Tests
7.6.4.11 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Ultrasound
7.6.5.2 Mammography
7.6.5.3 MRI Scan
7.6.5.4 PET Scan
7.6.5.5 CT Scan
7.6.5.6 SPECT & Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Cancer Diagnostics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Tumor Biomarkers Tests (PSA Tests
7.7.4.2 CTC Tests
7.7.4.3 AFP Tests
7.7.4.4 CA-19 Tests
7.7.4.5 HER2 Tests
7.7.4.6 BRCA Tests
7.7.4.7 ALK Tests
7.7.4.8 CEA Tests
7.7.4.9 EGFR Mutation Tests
7.7.4.10 KRAS Mutation Tests
7.7.4.11 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Ultrasound
7.7.5.2 Mammography
7.7.5.3 MRI Scan
7.7.5.4 PET Scan
7.7.5.5 CT Scan
7.7.5.6 SPECT & Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Cancer Diagnostics Scope:
|
Report Data
|
Cancer Diagnostics Market
|
|
Cancer Diagnostics Market Size in 2025
|
USD XX million
|
|
Cancer Diagnostics CAGR 2025 - 2032
|
XX%
|
|
Cancer Diagnostics Base Year
|
2024
|
|
Cancer Diagnostics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Myriad Geneticsinc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratoriesinc., and BPS Bioscienceinc. Antibodies Inc., Networks LLC, Beckman Coulterinc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc. Genway Biotechinc., Microdrop LLC (imaware), Svar Life Science AB, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., GE Healthcare, Illuminainc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologiesinc., Aurora Imaging Technologiesinc., and Quest Diagnostics..
|
|
Key Segments
|
By Type
Tumor Biomarkers Tests (PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
By Applications
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
|
